Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Current Radiopharmaceuticals|March 16, 2015
Lutetium-177 Labeled Bombesin Peptides for Radionuclide TherapyTamila Stott Reynolds, Rajendra P Bandari, Zongrun Jiang, et al.Journal of Medicinal Chemistry|August 17, 2018
Design, Synthesis, and in Vitro and in Vivo Evaluation of High Affinity and Specificity Near-Infrared Fluorescent Bombesin Antagonists for Tumor ImagingHang Xu, Rajendra P Bandari, Li Lee, et al.Molecular Imaging and Biology|September 5, 2020
Development and Preclinical Evaluation of <sup>99m</sup>Tc- and <sup>186</sup>Re-Labeled NOTA and NODAGA Bioconjugates Demonstrating Matched Pair Targeting of GRPR-Expressing TumorsGeorge Makris, Rajendra P Bandari, Marina Kuchuk, et al.Nanomaterials (Basel, Switzerland)|July 26, 2024
Bimodal MRI/Fluorescence Nanoparticle Imaging Contrast Agent Targeting Prostate CancerHang Xu, Ping Yu, Rajendra P Bandari, et al.Bioconjugate Chemistry|January 12, 2021
Preclinical Evaluation of Novel <sup>64</sup>Cu-Labeled Gastrin-Releasing Peptide Receptor Bioconjugates for PET Imaging of Prostate CancerGeorge Makris, Antonio Shegani, Pavithra H A Kankanamalage, et al.Journal of Medicinal Chemistry|February 3, 2021
Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMARajendra P Bandari, Terry L Carmack, Anil Malhotra, et al.Nuclear Medicine and Biology|June 22, 2018
Matched-pair, <sup>86</sup>Y/<sup>90</sup>Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancerNilantha Bandara, Tamila J Stott Reynolds, Rebecca Schehr, et al.Pageof 1